ATNM · AMEX
Actinium Pharmaceuticals (ATNM) Stock Price & Fundamentals
Actinium Pharmaceuticals (ATNM) closed at $608.40 on Oct 9, 2026, up 0.37% from the previous close of $606.16.
Share price, past year
1Y +40.66%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $608.40 |
| Sep 30, 2026 | $613.14 |
| Aug 31, 2026 | $600.15 |
| Jul 31, 2026 | $606.21 |
| Jun 30, 2026 | $611.53 |
| May 29, 2026 | $604.62 |
| Apr 30, 2026 | $591.92 |
| Mar 31, 2026 | $577.94 |
| Feb 27, 2026 | $533.36 |
| Jan 30, 2026 | $510.59 |
| Dec 31, 2025 | $493.58 |
| Nov 28, 2025 | $472.63 |
| Oct 31, 2025 | $441.43 |
Key statistics
- Market cap
- $19.13B
- P/E (TTM)
- 1,738.3
- EPS (TTM)
- $0.35
- Revenue (TTM)
- —
- Net income (TTM)
- $11.31M
- Shares outstanding
- 31.4M
- Dividend yield
- —
- 52-week range
- $424.86 – $627.86
Actinium Pharmaceuticals's market cap is $19.13B, based on a share price of $608.40 and 31.4M shares outstanding as of Jun 30, 2026.
Financials
Actinium Pharmaceuticals reported revenue of $90.00K for fiscal 2025.
Actinium Pharmaceuticals reported a net loss of $33.89M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $90.00K | +11.1% | −$33.89M | −37,652.2% | −$1.09 | −$24.68M |
| FY2023ended Dec 31, 2023 | $81.00K | −92.1% | −$48.82M | −60,269.1% | −$1.83 | −$47.49M |
| FY2022ended Dec 31, 2022 | $1.03M | −10.0% | −$33.02M | −3,205.5% | −$1.37 | $8.28M |
| FY2021ended Dec 31, 2021 | $1.14M | — | −$24.77M | −2,165.6% | −$1.20 | −$21.00M |
| FY2011ended Dec 31, 2011 | $0.00 | — | — | — | — | — |
| FY2010ended Dec 31, 2010 | $0.00 | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $35.00M | $27.90M | $0.89 |
| Q3 FY2025ended Sep 30, 2025 | $90.00K | −$5.13M | −$0.16 |
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $45.00K | — | — |
| Q2 FY2022ended Jun 30, 2022 | $45.00K | — | — |
| Q1 FY2022ended Mar 31, 2022 | $940.00K | — | — |
| Q4 FY2021ended Dec 31, 2021 | $23.00K | — | — |
| Q3 FY2021ended Sep 30, 2021 | $233.00K | — | — |
Company profile
- Name
- Actinium Pharmaceuticals, Inc.
- Ticker
- ATNM
- Exchange
- AMEX
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 100 Park Ave., 23rd Floor, New York, NY 10017
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001388320
Recent SEC filings
- Aug 14, 2026
- Aug 7, 2026
- Jun 18, 2026
- May 29, 2026
- May 8, 2026
- Mar 30, 2026
- Feb 13, 2026
- Nov 26, 2025
Frequently asked questions
What is Actinium Pharmaceuticals's stock price?
Actinium Pharmaceuticals (ATNM) closed at $608.40 on Oct 9, 2026, up 0.37% from the previous close of $606.16.
What is Actinium Pharmaceuticals's market cap?
Actinium Pharmaceuticals's market cap is $19.13B, based on a share price of $608.40 and 31.4M shares outstanding as of Jun 30, 2026.
How much revenue does Actinium Pharmaceuticals make?
Actinium Pharmaceuticals reported revenue of $90.00K for fiscal 2025.
What is ATNM's P/E ratio?
Actinium Pharmaceuticals's price-to-earnings ratio is 1,738.3, based on trailing twelve-month diluted EPS of $0.35.
Does Actinium Pharmaceuticals pay a dividend?
Actinium Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Actinium Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures